Marlowe Gateway Offers Luxury Living, Easy Access to St. Pete Conveniences
"We love
Marlowe Gateway is in a prime location close to the Gateway employment hub with plenty of dining options in the immediate area. The community is minutes from the
Apartments come in one-, two- and three-bedroom layouts that range from 765 to 1,279 sq. ft. with 20 percent of available homes dedicated to workforce housing. The 412 individual residences have screened in balconies or ground level patios that have direct access to amenities. Finishes include quartz countertops, GE appliances such as French door refrigerators, front load laundry machines, and luxury wood-styled flooring. Marlowe Gateway will feature two resort-styled pools, an expansive clubhouse featuring a detailed coworking program and a three-thousand square foot fitness complex. Multiple open courtyards and a dog park have also been programmed into this property.
Marlowe by Greystar provides suburban luxury living with quality newer finishes, spacious and current amenities and modern design with easy access to urban conveniences.
Marlowe Gateway is targeting a late 2023 opening date with final completion slated for summer 2024. For more information, or to join the early interest list to be notified of availability, please visit www.livemarlowegateway.com.
About Greystar
Greystar is a leading, fully integrated global real estate company offering expertise in property management, investment management, development, and construction services in institutional-quality rental housing, logistics, and life sciences sectors. Headquartered in
View original content to download multimedia:https://www.prnewswire.com/news-releases/marlowe-gateway-offers-luxury-living-easy-access-to-st-pete-conveniences-302036131.html
SOURCE Greystar
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gentoo Media Inc. agrees EUR 50 million senior secured loan and secures full underwriting commitments for a planned EUR 50 million share issue to refinance its December 2026 bonds
- Lundbeck announces headline results from Phase IV THRIVE trial evaluating VYEPTI® (eptinezumab) following inadequate response to prior CGRP-targeting preventive therapy
- Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share